



Australian  
**Atherosclerosis**  
Society Inc.

## Member Newsletter - March 2023

Welcome to the Autumn 2023 edition of the AAS newsletter. As we transition from a bustling grant writing season, it's the perfect time to update our members on recent developments. We were thrilled to reconnect with colleagues and friends, both new and old, at our first in-person meeting this past November after an extended hiatus.



This edition brings you insights from our new President, Judy de Haan, and highlights the achievements of our 2022 AAS meeting award winners. We also introduce an important milestone for the society—our position statement on lipoprotein(a)—and share an exciting travel support opportunity for our student and early career members.

Costan Magnussen, Newsletter Editor



### **Passing of the baton – Judy de Haan, new President of the AAS**

The AAS was honoured to have Steve Nicholls as our most recent President, but with increasing workload he has stepped down one year early. The AAS Executive nominated Judy de Haan to fill this position for 2023, which happily co-incides with her elected year as Incoming President. Both Steve and Peter Psaltis are remaining on the Executive as Past-Presidents to provide continuity and counsel when needed. Judy's thoughts on her role and the future of the AAS may be read here ...

[Read more](#)

---

## 2022 Rising Stars

The presentations at the 2022 Annual Scientific Meeting were outstanding. None better than those awarded our Rising Star Awards, supported by CSL. Congratulations to all finalists, with special applause to the winners.

### **HDR award winner: Camilla Bertuzzo Veiga (Baker Heart and Diabetes Institute)**

“The AAS 2022 meeting was a wonderful opportunity to hear and meet amazing researchers in the field of atherosclerosis! The meeting had a great atmosphere, and it was easy to interact with all the attendees. I could interact and engage in vibrant discussions with many students and leaders in the field, it was very exciting! I was thrilled to receive the HDR award, it not only recognizes the work I have been doing in the last 5 years but also keeps me motivated to continue my career with atherosclerosis. Thank you, AAS for putting together such a well thought out and engaging meeting!”



### **ECR award winner: Jeffrey Wang (ANZAC Research Institute)**

“I’d have to say that out of all of the scientific meetings I’ve been to so far, this is one of the best experiences I’ve had. Everyone was super friendly and shared thought provoking ideas, and the venue certainly created a cohesive environment that facilitated interactions. I really enjoyed meeting so many different people and learning about their research endeavours, and equally appreciated their engagement with mine to encourage potential collaborations. Certainly look forward to the next meeting!”



---

## Lp(a) Position Statement

We are pleased to inform our members about the recently published position statement by our society in Heart, Lung and Circulation, which centres on lipoprotein(a) in atherosclerotic cardiovascular disease. This vital statement addresses the challenges of measuring and treating elevated lipoprotein(a), providing targeted testing and management guidelines for high-risk adult

---

patients. This important milestone for our society holds significant value for cardiologists and related specialists. We extend our congratulations to the dedicated team behind this remarkable achievement.

[Lp\(a\) statement](#)

---

### **AAS Trust Travel Grants Round 1 closes April 30.**

Planning on presenting at an international conference? You may be eligible for an AAS Trust Travel Grant.

[Read more](#)



---

**Don't be shy - share your news with the AAS community -**  
*add your Twitter handle to your profile in the Members Portal.*  
*And tag us in your posts (@atheroaustralia).*

We love to see what our members are up to. Got a new paper or other exciting news? A grant, a recent paper or a lab highlight or achievement (pictures welcome)? Let us know over social media or via [admin@athero.org.au](mailto:admin@athero.org.au) and we'll help get the word out.

---

The AAS wishes to thank and acknowledge the 2023 Atherosclerosis Education Program Partners, supporting all activities – Scientific Showcase Seminars, Clinical Masterclass, FH Summit and Annual Scientific Meeting.

The AMGEN logo is displayed in a bold, blue, sans-serif font.

The NOVARTIS logo features a stylized blue and orange 'N' icon followed by the word 'NOVARTIS' in a blue, sans-serif font.

This message was sent to you by the {Organization\_Name}

If you no longer wish to receive these emails, you can [unsubscribe](#) at any time

{Organization\_URL} {Organization\_Contact\_Email}